Pilot Study of Extended-release Exenatide to Improve Glucose Control and Reduce Systemic Inflammation in Diabetic, HIV-infected Adults on Antiretroviral Therapy
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Change in serum interleukin 6 (IL-6) and highly-sensitive C-reactive protein (hsCRP) levels
The primary outcome will be the change in serum IL-6 and hsCRP levels from baseline (pre-treatment) to 16 weeks of Bydureon treatment.
John Koethe, MD
Vanderbilt University School of Medicine
United States: Institutional Review Board
|Vanderbilt University||Nashville, Tennessee 37232-6305|